MicroRNAs as diagnostic markers and therapeutic targets for traumatic brain injury

Bridget Martinez1, Philip V. Peplow1,2
1 Department of Molecular and Cellular Biology, University of California, Merced, CA, USA
2 Department of Anatomy, University of Otago, Dunedin, New Zealand

How to cite this article: Martinez B, Peplow PV (2017) MicroRNAs as diagnostic markers and therapeutic targets for traumatic brain injury. Neural Regen Res 12(11):1749-1761.

Abstract
Traumatic brain injury (TBI) is characterized by primary damage to the brain from the external mechanical force and by subsequent secondary injury due to various molecular and pathophysiological responses that eventually lead to neuronal cell death. Secondary brain injury events may occur minutes, hours, or even days after the trauma, and provide valuable therapeutic targets to prevent further neuronal degeneration. At the present time, there is no effective treatment for TBI due, in part, to the widespread impact of numerous complex secondary biochemical and pathophysiological events occurring at different time points following the initial injury. MicroRNAs control a range of physiological and pathological functions such as development, differentiation, apoptosis and metabolism, and may serve as potential targets for progress assessment and intervention against TBI to mitigate secondary damage to the brain. This has implications regarding improving the diagnostic accuracy of brain impairment and long-term outcomes as well as potential novel treatments.

MicroRNAs in TBI
The initial severity and prognosis of TBI in humans is classified on the Glasgow Coma Scale (GCS) that is based on three tests: ocular, verbal, and motor responses. The sum of the three values is the GCS score. The injury is classified as severe with GCS 3–8, moderate GCS 9–12, or mild GCS 13–15 (Bilgin et al., 2012). The GCS covers a broad severity range of fall-related TBI in persons aged ≥ 75 (Adekoya et al., 2008; Ribbers, 2010) with a very high number of brain injuries resulting from motor vehicle accidents and sporting activities. There has also been a marked increase in the incidence of fall-related TBI in persons aged ≥ 75 (Adekoya et al., 2002). The severity of TBI is determined by the nature, speed and location of the impact, and by complications such as hypotension, intracranial hemorrhage or increased intracranial pressure. TBI is characterized by primary damage to the brain from the external mechanical force and by subsequent secondary injury due to various molecular and pathophysiological responses that eventually lead to neuronal cell death. These responses include brain edema, intracranial hypertension, and subsequent neurological dysfunction (Zweckberger et al., 2006). Secondary brain injury events may occur minutes, hours, or even days after the trauma (Ribbers, 2010), and provide valuable therapeutic targets to prevent further neuronal degeneration. However, treatment options for secondary brain damage have failed to show efficacy in clinical trials (Maas et al., 1999), thereby emphasizing a need for new therapeutic targets.

MicroRNAs are short non-coding RNAs (20–24 nucleotides) that negatively regulate gene expression at the post-transcriptional level by binding to the 3’ untranslated region (UTR) of target mRNAs which leads to degradation of the mRNA or direct inhibition of mRNA translation (Baek et al., 2008). They control a range of physiological and pathological functions such as development, differentiation, apoptosis and metabolism (Ambros, 2004). We have searched the PubMed database for recently published studies of microRNAs during the first few days or weeks after TBI in humans and experimental animals, and whether they can serve as potential targets for progress assessment and intervention against TBI to mitigate secondary damage to the brain. This has implications regarding improving the diagnostic accuracy of brain impairment and long-term outcomes as well as potential novel treatments.
symptoms from subtle to more serious conditions in some cases accompanied with temporary loss of consciousness (Gennarelli, 2014). Sports-related and other minor traumatic brain injuries with GCS scores in the 13–15 range occur in 1.6 to 3.8 million young healthy individuals annually (Leo and McCrea, 2016). Mild TBI is characterized by loss of consciousness for < 30 minutes and post-traumatic amnesia for < 24 hours and accounts for approximately 75–90% of the total TBI cases (Fischer, 2013). Computed tomography and magnetic resonance imaging have limited sensitivity to detect mild TBI (Kesler et al., 2000; Yuh et al., 2012). Mild TBI is often unnoticed or misdiagnosed due to the absence of specific diagnostic markers.

In experimental animal models, the extent of brain injury is classified according to the parameters used, together with behavioral testing and histological examination of brain sections. For example, in the controlled cortical impact (CCI) procedure which uses a pneumatic controlled cortical impact device to deliver mechanical energy to the intact dura, the amount of brain deformation is a function of the impactor tip size, contact velocity and duration time (Lighthall, 1988; Davis et al., 2008; Gilmer et al., 2009). By varying these parameters different severity grades of TBI injury have been produced in mice and rats. Another procedure is the weight drop injury (WDI) method in which a metal rod is dropped from a known height above the exposed skull of the animal to create a brain injury (Marmarou et al., 1994). Different severity grades of TBI injury have been produced in mice by varying the weight, diameter of tip, and fall height of the impactor rod. The weight drop method was found to recreate the cognitive and behavioral deficits seen in human patients with mild TBI (Yang et al., 2013; Sharma et al., 2014). A third method is the fluid percussion injury (FPI) method, which involves craniotomy to expose the dura and placement of a female Luer lock or plastic cap that is cemented in place over the craniotomy site; this is followed by transient compression and/or deformation of the underlying brain using a fluid-mediated pressure pulse, with a pulse duration time of approximately 20 ms (Kabadi et al., 2010; Alder et al., 2011).

**Human studies**

Six studies were found and mostly comprised both male and female patients with ages ranging from 14 to 65 years (Table 1). The two largest studies were performed with 76 patients (59 males/17 females, mean age 49 years; Yang et al., 2016) and 70 patients (51 males/19 females, mean age 41 years; Di Petro et al., 2017). Of the six studies, five had patients with mild TBI and severe TBI classified on the GCS and two of these also included patients with moderate TBI. The remaining study comprised only patients with severe TBI. These studies showed that serum or plasma levels of specific microRNAs could serve as potentially valuable indicators of the diagnosis, severity, and prognosis of TBI. Serum/plasma levels of miR-93, -191, -499, -765 could be used to distinguish between patients with severe, moderate or mild TBI (Redell et al., 2010; Sun et al., 2016; Yang et al., 2016; Di Petro et al., 2017). Moreover, cerebro-spinal fluid (CSF) levels of miR-141, -1297, -228, -362-3p, -451, -486 were identified as distinguishing severe TBI patients from controls (Bhomia et al., 2016; You et al., 2016). In addition, serum levels of miR-93, -191, -499, -425-p were indicative of outcome in TBI patients (Yang et al., 2016; Di Petro et al., 2017). MicroRNAs with upregulated and downregulated expression in patients with mild and severe TBI are shown in Figure 1.

**Animal studies**

Fifteen studies were found which had mostly used male mice and rats (Table 2). Ten of these studies had used the CCI method, three the WDI method, and two the FPI method to create the brain injury. The ages of the mice ranged from 8 to 24 weeks (adult) and 22–24 months (aged), and for the rats the ages ranged from 7 to 12 weeks (adult).

**CCI studies**

The CCI parameters ranged from 3 to 5 mm for diameter of impactor tip, 0.8 to 6 m/s for impact velocity, 85 to 200 ms for duration time, and deformation depth of cortex 1 to 2 mm. By comparison with the parameters used by Liu et al. (2014) to induce a moderate TBI by CCI (equivalent to...
### Table 1 MicroRNAs in human patients with traumatic brain injury (TBI)

| Reference            | No. of patients, gender, ages | Comparison | Changes in miRNAs in patients | Functional outcomes | Conclusion |
|----------------------|-------------------------------|------------|-------------------------------|---------------------|------------|
| Di Petro et al. (2017) | 27 M/1 F, 40 years (mean); 24 M/11 F, severe TBI with EC injury, 41 years (mean). Serum was collected from patients. Patient outcomes assessed at 6 months post-injury by Glasgow Outcome Scale (GOS). | 22 M/13 F healthy volunteers (HV), 15 M/15 F EC injury patients. Initial screening of serum microRNAs performed on 5 mild TBI + EC and 5 severe TBI + EC patients and compared to controls at days 1 and 15 post-injury by microarray analysis and RT-PCR. Ten differentially expressed microRNAs were chosen as potential candidate biomarkers. miR-21 and miR-335 was significantly downregulated at 0–12 hours compared to controls or severe TBI + EC, and miR-502 was downregulated at 0–1 and 4–12 hours compared to controls or severe TBI + EC. After 48 hours from mild TBI, miR-425-p and miR-502 returned to normal levels. MiR-21 and miR-335 were analysed as potential biomarkers of severe TBI since they were both upregulated at both time points in the initial screening and also in the second set of patients. MiR-21 was significantly upregulated in severe TBI in serum at 4–12 hours, 48–72 hours and day 15 after injury compared to controls and mild TBI + EC. MiR-335 was upregulated in severe TBI + EC at 0–1 hour, 4–12 hours, 48–72 hours and day 15 compared to HV and mild TBI + EC, but not EC. | MiR-24-5p at 0–1 hour was strongly predictive of 6-month outcome. However, miR-502, -21 and -335 did not show any prognostic value at this time point. At a later time point of 4–12 hours, miR-425-p returned to normal levels, and miR-21 also became highly predictive, while miR-502 and miR-335 remained non-significant. | MiR-42-5p and miR-502 could be considered the most promising candidate biomarkers for the early diagnosis and monitoring of mild TBI. MiR-21 and miR-335 are valid biomarkers for the diagnosis of severe TBI. In addition, miR-42-5p is a strong predictor of 6-month outcome at 0–1 hour and 4–12 hours, while miR-21 is predictive of outcome at 4–12 hours. |
| You et al. (2016)     | 14 M/12 F, severe (coma) TBI, 49 years (mean). Cerebro-spinal fluid (CSF) samples collected by lumbar puncture. | 12 M/9 F 50 years (mean) with headache, vertigo, spinal pain, tinnitus as controls. CSF samples collected. By microarray analysis of CSF, expression of 14 microRNAs in severe (coma) TBI group differed from that of controls: 10 had higher and 4 had lower expression compared with controls. Of the upregulated microRNAs, miR-141 and miR-257 showed the greatest fold changes of 4.62 and 3.05 that of controls, with the other microRNAs increased from 2.0 to 2.5-fold. Of the downregulated microRNAs, miR-297 had the greatest fold change of -3.44 that of controls, with the others decreased by 2.1 to 2.6 fold. | One single nucleotide polymorphism (SNP) (rs11851174 allele: C/T) was identified in the motif area of microRNA has-miR-431-3p gene promoter region. The altered microRNA expression levels in CSF of TBI patients together with SNP identified within the microRNA gene promoter area provide a new perspective on the mechanism of impaired consciousness after TBI. | |
| Yang et al. (2016)    | 59 M/17 F, 49 years (mean): 25 mild TBI, 25 moderate TBI, 7 severe TBI. Serum samples collected within 24 hours and then daily for up to 21 days after injury. Patient outcomes assessed at 9 months post-injury by GOS. | 29 M/9 F 47 years (mean) with no evidence of disease. Serum levels of miR-93, -191 and -499 measured by RT-PCR were significantly increased in TBI patients compared to controls over the study period. The levels of these microRNAs were markedly increased within 24 hours after injury and reached peak levels 48 hours after injury (7.2 to 14) but remained significantly elevated compared to controls. The levels of these microRNAs were higher in severe TBI patients than in the moderate and mild TBI patients. Serum levels of miR-93, -191 and -499 were higher in patients with poor clinical outcome (GOS 1–3) than in those with good outcome (GOS 4–5). | Serum levels of miR-93, -191 and -499 are potentially valuable indicators of the diagnosis, severity, and prognosis of TBI. | |
| Sun et al. (2016)     | 28 M/20 F 18–50 years: 16 mild TBI, 16 moderate TBI, 16 severe TBI with injury occurring within the preceding 24 hours. Plasma samples collected from patients. | 20 age-matched healthy subjects. Plasma level of miR-23b measured by RT-PCR was downregulated in TBI patients compared to controls. The miR-23b level was significantly decreased in severe TBI patients compared to mild or moderate TBI patients. | MiR-23b specifically targeted to 3’UTR of ATG12 mRNA and modified its translation. MiR-23b might be a potential therapeutic target for TBI. | |
| Blonnia et al. (2016) | 7 M/7 F, 75% mild TBI and 25% moderate TBI, 36 years (mean); 8 M severe TBI, 39 years (mean). Serum samples of mild/moderate TBI were collected within 24 hours from injury. Serum and CSF samples were taken from an archived set of a completed severe TBI study. Serum samples were collected within 48 hours (mean 24 hours) and CSF samples collected within 48 hours of injury. Normal healthy control serum (n = 8) and normal control CSF (n = 6) samples. By microarray analysis, 39 and 37 microRNAs were significantly upregulated in serum samples of mild/moderate TBI and severe TBI respectively. A comparison was performed between the serum microRNAs upregulated in both mild/moderate TBI and severe TBI which identified 10 microRNAs (miR-151, -195, -20a, -328, -362-3p, -304, -451, -486, -505, -92a) with increased expression in both mild/moderate and severe TBI. RT-PCR demonstrated that all the selected microRNAs were significantly upregulated in serum TBI samples; however, the fold upregulation changes were not the same as in the initial profiling. These 10 microRNAs were validated in CSF from severe TBI and 4 microRNAs (miR-328, -362-3p, -451, -486) were found to be upregulated in CSF. | The mature miRNAs predicted to be targeted by the upregulated microRNAs are involved in major TBI related pathways such as erythropoietin signaling, G protein coupled receptor signaling, GABA receptor signaling and neuropathic pain signaling in dorsal horn neurons. A panel of 10 unique microRNAs was identified for the diagnosis of mild/moderate TBI and severe TBI. | |
| Rodell et al. (2010)  | 11 mild TBI > 14 years, 10 severe TBI, 14–65 years. Plasma was collected from mild TBI patients within 10 hours of injury. For severe TBI patients, plasma was obtained at the earliest possible time after admission and patient stabilization. | 108 unique microRNAs were detected in control plasma and 8 unique microRNAs in severe TBI plasma at 68 ± 8 hours post-injury. Five candidate microRNAs (miR-16, -26a, -92a, -638, -765) were chosen for further analysis by RT-PCR. The plasma levels of miR-16, -92a and -765 were significantly altered in severe TBI patients compared to controls (the first two were decreased, the third increased). The levels of miR-26a and miR-638 were not significantly altered at the time points examined (0–24 hours, 25–48 hours, 49–72 hours). RT-PCR of plasma samples collected from mild TBI patients within 10 hours of the time of injury showed the levels of miR-16 and miR-92a were significantly increased in mild TBI patients. Combining plasma levels of miR-16, -92a and -765, 100% sensitivity and 100% accuracy could be achieved in identifying severe TBI patients. Poor diagnostic accuracy was found for miR-16 and miR-92a in differentiating between mild TBI patients and orthopedic injury patients. Plasma microRNAs have the potential to improve TBI patient classification and possibly clinical management. | Combining plasma levels of miR-16, -92a and -765, 100% sensitivity and 100% accuracy could be achieved in identifying severe TBI patients. Poor diagnostic accuracy was found for miR-16 and miR-92a in differentiating between mild TBI patients and orthopedic injury patients. Plasma microRNAs have the potential to improve TBI patient classification and possibly clinical management. |
**Table 2 MicroRNAs in animal models of traumatic brain injury (TBI)**

| Reference | No. of animals, gender, ages | Comparison | Changes in miRNAs in animals | Functional outcomes | Conclusion |
|-----------|-------------------------------|------------|-------------------------------|---------------------|------------|
| Sahinhanov et al. (2016) | C57B/6 mice, male, 12 weeks. | A 4-mm craniotomy made on central aspect of left parietal bone. | Sham animals underwent same procedures but without CCI and served as controls. | By microarray analysis, the level of miR-711 was upregulated in the cortex of TBI animals compared to uninjured controls. Using RT-PCR, there was a rapid upregulation of miR-711 starting as early as 1 hour post-injury, peaking at 6 hours, and persisting through to 72 hours. | Changes in miR-711 contribute to neuronal cell death after TBI in part by inhibiting Akt, and may serve as a novel therapeutic target. | |
| Meissner et al. (2016) | C57B/6 mice, male, 9–12 weeks. | A craniotomy made over the right parietal cortex, leaving the dura intact. CCI parameters were diameter of impactor tip 3 mm, impact velocity 0.8 m/s, duration 150 ms, deformation depth 1.3 mm to produce mild-moderate TBI. Mice were sacrificed at 6 and 12 hours after TBI. | Sham-operated animals that did not receive CCI (n = 6) and healthy untreated animals was performed. Of the 780 microRNAs represented in the array, 410 were detected in all samples. Two-way hierarchical clustering was applied to the normalized expression values of the 50 most differentially expressed microRNAs across the whole cohort of samples. The two main clusters reflect the difference between the control groups and samples obtained after TBI. Principal component analysis revealed that the 6 hours group was closer to the 12 hours group than to the 1 hour group. 158 microRNAs were differentially expressed between sham and TBI groups. Of these microRNAs, 66 were upregulated and 92 were down-regulated in TBI groups compared to sham. The microarray analysis was validated by RT-PCR. This confirmed the upregulated expression of miR-2137, -451, -218, -144, -184, and the down-regulated expression of miR-21, -92a, -138, -124 and let-7c could be involved in the prevention and protection exercise in TBI model. | MicroRNA-2137 showed the highest upregulation after TBI (up to 25-fold). In situ hybridization for miR-2137 on frozen brain sections revealed a constitutive cytoplasmic expression of miR-2137 with a neuronal staining pattern throughout the brain in healthy and sham animals. At 6 hours after TBI, the neuronal staining pattern increased in the penumbral tissue of the contusion and in the adjacent hippocampus. | The microRNA expression levels in the contused cortex after TBI may aid the identification of novel targets for the management of brain trauma. | |
| Miao et al. (2015) | C57B/6 mice, male, 17–39 weeks housed in cages equipped with a running wheel (RW). After 3 weeks, exercised animals divided into two groups: sham procedure (sham-runners) and TBI (TBI-runners). A 3.5-mm craniotomy made on left parietal bone leaving the dura intact. CCI parameters were diameter of impactor tip 3 mm, impact velocity 4.5 m/s, deformation depth 1.5 mm to produce moderate TBI. There were 30 mice in each group: 3 used for microRNA analysis and the remainder for behavioral and survival analyses. | Animals exposed to an immobilized RW. Unexercised animals divided into two groups: sham-runners and TBI-non-runners. | Effects of exercise on microRNA expression profiles in sham and TBI mice were detected. 87 microRNAs were differentially expressed between the sham non-runner and sham-runner groups: 61 and 26 microRNAs were up- and down-regulated, respectively. Also 33 microRNAs were differentially modulated between TBI-non-runner and TBI-runner groups: 20 microRNAs were up- and 13 down-regulated, respectively. Expressions of miR-21, -92a, -138, -124, -874, let-7c were measured by RT-PCR. In the TBI-non-runner group compared to sham non-runners, miR-21, -92a and -874 were increased while miR-138, -124 and let-7c were significantly decreased. However, in the TBI-runner group the levels of miR-21, -92a and -874 decreased while those of miR-138, -124 and let-7c increased compared with the TBI-non-runner group. | After 14 days, there was 55% survival in TBI-runners group and 30% survival in TBI-non-runners group. RW prior to sham injury did not have an effect on recovery of righting reflex in sham animals, but the rating time was shorter in TBI-runners. | MicroRNAs such as miR-21, -92a, -674, -138, -124 and let-7c could be involved in the prevention and protection afforded by voluntary exercise in TBI model. |
Table 2 Continued

| Reference | No. of animals, gender, ages | Comparison | Changes in miRNAs in animals | Functional outcomes | Conclusion |
|-----------|-----------------------------|------------|-----------------------------|---------------------|------------|
| Hu et al. (2015) | C57Bl/6 mice, male, 17-19 weeks housed in cages equipped with RW (n = 7). Cranioectomy performed and left parietotemporal cortex subjected to CCI using parameters diameter of impactor tip 3 mm, impact velocity 6 m/s, deformation depth 2 mm to produce moderate TBI. TBI runners were injected i.p. with miR-21 mimic (5 nmol/20 g body wt), miR-21agomir (10 nmol/20 g body wt), or RNA-oligonucleotides negative control (miR-NC) 5 hours post-TBI and twice/week before sacrifice. Behavioral tests performed at 1-20 days post-injury immediately after running. Mice sacrificed and brains removed. | Shan-operated animals did not receive CCI and housed in cages equipped with RW (sham runners, n = 7). Sedentary control, sham-non-runners, and TBI-non-runners were exposed to immobilized RW (n = 7/group). | By RT-PCR, the level of miR-21 was significantly increased in hippocampus of TBI non-runners compared with that of sham ones. The increase in miR-21 expression in hippocampus was reversed in TBI runners but did not reach the level of the sham group. | In Morris Water Maze test, TBI runners administered miR-21 agomir performed significantly better compared to those treated with miR-21 NC from days 15 to 20 post-injury. Treatment with miR-21 mimic post-injury significantly deteriorated maze performance compared to miR-21 NC treated animals. | The elevated level of miR-21 in hippocampus post-TBI was reduced by spontaneous RW exercise. Overexpression of miR-21 in TBI mice with spontaneous RW induced deterioration in spatial learning and memory retention. MiR-21 down-regulation reversed these effects. MiR-21 has been involved in neuroprotection induced by voluntary RW exercise post-TBI. |
| Sandhir et al. (2014) | C57Bl/6 mice, male, 20-24 weeks (n = 24) and 22-24 months (n = 24). A cranioectomy was made lateral to mid-sagittal suture, and animal subjected to CCI with parameters diameter of impactor tip 3 mm, impact velocity 1.5 m/s, duration 85 ms, deformation depth 1 mm to produce mild-moderate TBI. The tip contact area included motor and sensory cortical areas. Animals were sacrificed 1, 3, 5, 7 days post-injury and brains removed. There was no mortality in any of the groups. | Normal healthy control serum (n = 8) and normal control CSF (n = 6) samples. | | | |
| Sabirzhanov et al. (2014) | C57Bl/6 mice, male, 12 weeks. A 4 mm craniotomy was made on the central aspect of left parietal bone and subjected to CCI using parameters diameter of impactor tip 3.5 mm, impact velocity 6 m/s, deformation depth 2 mm to produce moderate TBI. At 15 minutes after injury, mice received a single i.c.v. injection of miR-23a-3p, miR-27a-3p, or negative control miR mimics. All drugs made up in CSF and injected into left ventricle at 0.5 µL/min, with a final volume of 5 µL, 0.1 mM mimic solution. Mice were sacrificed and brains removed. Sections of brain were stained with cresyl violet to quantify lesion volume. | Shan-operated animals did not receive CCI. | By microarray analysis, levels of miR-23a and miR-27a in cortex of TBI mice were downregulated at 1 hour, 6 hours, 24 hours post-injury compared to control. These changes were confirmed by RT-PCR with rapid downregulation of miR-23a-3p and miR-27a-3p starting as early as 1 hour after injury and lasting up to 24 hours, followed by recovery at 72 hours after injury. RT-PCR showed no significant changes after TBI in the expression profile of miR-24. By RT-PCR, i.c.v. injection of miR-23a and miR-27a mimics at 15 min post-injury completely reversed the TBI-induced decline in miR-23a and miR-27a, respectively, compared with TBI mice injected with negative control miR mimic. Injection of miR-23a-3p and miR-27a-3p mimics significantly attenuated TBI-induced upregulation of PUMA, Noxa, Bax, and active Bax protein levels. | TMiR-21 regulates cell survival, invasiveness and apoptosis through specific mRNA targets that include PTEN, PDCD4, RECK and TIMP3. PTEN was upregulated by 3.8-fold in the adult brain 24 hours post-injury. The expression was 96-fold higher in the aged brain. PDCD4 was not upregulated in the adult brain, but was upregulated 28-fold in the aged brain 24 hours post-injury. TIMP3 and RECK were upregulated 20-fold and 6-fold in the aged brain 24 hours post-injury, but no significant effect was observed in adult brain. | The mRNA expression levels for several Bcl-2 family proapoptotic proteins in the cortex were analysed at different time points after TBI. By RT-PCR, there was rapid upregulation of BH3-only family members, Noxa, Bax and Bim, with peak levels at 6 hours after injury, followed by progressive decrease toward normal levels at 24 hours after injury. PUMA mRNA reached its peak at 1 hour after injury, and Bak mRNA (a proapoptotic multi-BH domain member) reached its peak at 1 hour after injury and remained elevated thereafter. The miRNA data were confirmed by quantitative measurement of protein levels of several key proapoptotic proteins using Western blot. Injection i.c.v. of miR-23a-3p mimic significantly reduced TBI-induced lesion volume at 28 days after injury compared with negative control miR mimic. Administration of miR-23a-3p mimic significantly attenuated TBI-induced neuronal loss in CA1/2 and dentate gyrus of hippocampus at 28 days after injury compared with negative control miR mimic. | TMiR-21 response appeared blunted in the aged brain following TBI that resulted in upregulation of miRNA targets. Strategies aimed at upregulation of miR-21 and/or down-regulation of its targets might be useful in improving outcomes in the elderly after TBI. Post-injury decreases in miR-23a and miR-27a contribute to neuronal cell death after TBI by upregulating proapoptotic Bcl-2 family members, thus providing a novel therapeutic target. |
| Reference                  | No. of animals, gender, ages | Comparison                                   | Changes in miRNAs in animals                                                                 | Functional outcomes                                                                 | Conclusion                                                                 |
|----------------------------|------------------------------|----------------------------------------------|------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Wang et al. (2015)         | Sprague-Dawley rats, male, 9–11 weeks | A 6 mm craniotomy was made lateral to sagittal suture and centered between bregma and lambda, keeping the dura intact. CCI parameters were diameter of impactor tip 3 mm, impact velocity 3.5 m/s, deforation depth 2 mm to produce moderate TBI. At 12 hours post-injury, animals sacrificed and hippocampus removed (n = 5). | Naive uninjured animals as controls (n = 5). TBI resulted in altered expression levels of miRNAs in both hippocampal mitochondria and cytosol fractions at 12 hours following injury. RT-PCR revealed that the differential expression was reduced to normal levels of miRNAs in cytosol relative to mitochondria increased from 2.5-fold in naive samples to 4.2-fold in injured hippocampus. The levels of most mitochondria-associated miRNAs were decreased at this early time point following TBI. In particular, mitochondrial miRNAs such as miR-142-3p, -142-5p, -146a were decreased more than 2-fold following TBI, while these miRNAs increased in cytosol. The levels of several mitochondria-associated miRNAs were found to increase following TBI. A mong them, miR-155 and miR-223 levels were significantly increased at 7.3- and 4.3-fold, respectively, in mitochondrial fractions of injured compared to naive (uninjured) rats. RT-PCR was used to detect miR-155, -223, -146a, -142-3p, -142-5p, -150, -124a expression in enriched cortical neuron, astrocyte and microglial cultures. MiR-155, -223, -146a, -142-3p, -142-5p, -150 were detected in all three cell types but showed the highest expression in microglial and astrocytes. Levels of miR-124a were highest in cortical neurons. | MiR-155 is known to participate in the regulation of inflammatory responses. | At 12 hours following TBI, several microRNAs are significantly altered in hippocampal mitochondria and cytoplasm. In addition, levels of miR-155 and miR-223, both of which play a role in inflammation processes, are significantly increased in both the cytoplasm and mitochondria. |
| Sun et al. (2014)           | Sprague-Dawley rats, male/female, 7–8 weeks | A 4 mm × 4 mm craniectomy was performed over left parietal bone, keeping the dura intact. CCI parameters were impact velocity 3.5 m/s, duration 200 ms, deformation depth 2 mm to produce moderate TBI of left temparoparietal cortex. Animals were sacrificed at 1 hour, 1 day, 3 days, 5 days and 7 days post-injury (n = 15/group) and ipsilateral hippocampus removed. Two of TBI animals died of injury. Five animals of each group were used for molecular studies. | Sham-operated animals did not receive CCI (n = 5). By microarray analysis, a total of 205 microRNAs were identified. At day 1 post-injury, 41 microRNAs were more than 1.5-fold upregulated and 31 microRNAs were more than 1.5-fold downregulated; at day 3 post-injury, 81 microRNAs were more than 1.5-fold upregulated and 71 microRNAs were more than 1.5-fold downregulated; at days 5 post-injury, 52 microRNAs were more than 1.5-fold upregulated and 41 microRNAs were more than 1.5-fold downregulated. RT-PCR was used to validate the microarray results of miR-142-3p and miR-221. A strong correlation was found between the microarray profiling and RT-PCR data. The level of miR-142-3p in hippocampus showed a downregulation at days 1 and 3 followed by upregulation at day 5 post-injury. MiR-221 was persistently upregulated in hippocampus at all three time points post-injury. | MiR-221 has pro-proliferative and pro-migratory roles in different cell types and is also an anti-apoptotic microRNA. | Temporal expression of miR-142-3p may be used as a molecular marker for assessment of TBI progression and inference of damage time. MiR-221 may play a key role in regulating cell proliferation and angiogenesis by PDGFB signaling pathway at the early stages after TBI. |
| Liu et al. (2014)           | Sprague-Dawley rats, male/female, 7–8 weeks | A 4 mm × 4 mm craniectomy was performed over left parietal bone, keeping the dura intact. CCI parameters were impact velocity 3.5 m/s, duration 200 ms, deformation depth 2 mm to produce moderate TBI of left tempoparietal cortex. Animals were sacrificed at 1 hour, 1 day, 3 days, 5 days and 7 days post-injury (n = 15/group) and ipsilateral hippocampus removed. Two of TBI animals died of injury. Five animals of each group were used for molecular studies. | By microarray analysis, 156 microRNAs were detected in sham and the five TBI groups. Of these, 60, 41, 81, 52 and 60 microRNAs were upregulated (> 1.5-fold) while 45, 31, 41 and 35 were downregulated (< 1.5-fold) at 1 hour, 1, 3, 5 and 7 days post-injury. There were 10 microRNAs that were consistently up/down-regulated (≥ 1.5-fold) at all five time points after injury, among which miR-142-3p, -144, -340-5p, -674-5p, -153, -186, -190, -132a, -138-1p were upregulated whereas let-7b was downregulated. RT-PCR was used to confirm the microarray findings for three selected microRNAs (miR-144, -153 and -340-5p). The expression levels of all three microRNAs in ipsilateral hippocampus were significantly elevated at all five time points after TBI compared to sham controls. | There was no significant lesion or cell death in hippocampus of sham group on H&E staining of sections. Neuronal cell death was observed at 1 hour after TBI and it increased time-dependently from 1 hour to 3 days post-TBI. At 7 days after injury, the hippocampus structures were almost complete and neurons tended to control. Predicted target genes included Cask, Nef2, 221 and Snca. Western blot results showed a significant decrease in protein expression of Cask in hippocampus at 1 hour, 1 day, and 3 days post-injury compared to control group. A decrease was detected in expression of Nef2, the protein of 221 gene that is a putative target of both miR-144 and miR-153, in hippocampus post-injury. SNA, one of the target proteins of miR-153, was also significantly suppressed in hippocampus after TBI. | MiR-144, -153 and -340-5p might serve as potential targets for progress assessment and intervention to mitigate secondary damage after TBI. |
| Hu et al. (2012)            | Sprague-Dawley rats, male, 8–9 weeks | A 4 mm craniotomy was made over left tempoparietal cortex. CCI parameters were diameter of impactor tip 3 mm, impact velocity 3.5 m/s, duration 200 ms, deformation depth 2 mm to produce moderate TBI. Animals were sacrificed at 1 day and 7 days post-injury and brain tissue from dorsal hippocampus collected (n = 3–4/group). | Sham-operated animals did not receive CCI (n = 3–4). By microarray analysis, 328 microRNAs were identified. RT-PCR was used to validate the results of deep sequencing by measuring the expression levels of differentially expressed microRNAs. Microarray parameters were upregulated (≥ 1.5-fold) at all five time points after injury, expression of both miR-135a and miR-135b was reduced at 7 days post-injury; miR-124 expression was comparable in control and TBI samples at both 24 hours and 7 days time points. These results were consistent with findings from deep sequencing. Using deep sequencing, 13 microRNAs were downregulated and 8 microRNAs were upregulated at 24 hours post-injury. Among the 21 microRNAs altered at 24 hours, 5 (miR-144, -146, -148b-5p, -142-5p, -221a) showed persistent changes at 7 days post-injury. Number of different microRNAs was reduced to 10 (7 down-regulated, 3 upregulated) at 7 days post-injury. | Gene ontology enrichment analysis showed that at the early times after brain injury, microRNAs might be involved in inhibition of white blood cell apoptosis to augment the inflammatory response, dampening of transcription and translation of protein folding and catabolism to reduce stress-induced denaturation and aggregation of intracellular proteins, and promotion of aerobic respiration to exert protective actions. At the later times after injury, microRNAs preferentially regulate gene expression, intracellular trafficking and metabolism, cytoskeleton and cell adhesion to allow cell structure remodeling and synaptogenesis for repair of neuronal circuitry. | In addition to known pathophysiological changes, several cellular pathways that are subjected to modification by differentially expressed microRNAs in brains of TBI animals have been identified. These can potentially be targeted for development of novel treatment of TBI. |
### Table 2 Continued

| Reference                        | No. of animals, gender, ages | Comparison | Changes in miRNAs in animals | Functional outcomes | Conclusion |
|----------------------------------|------------------------------|------------|------------------------------|---------------------|------------|
| Chandran et al. (2017)           | C57B/6J mice, male, 10–12 weeks | Sham operated animals did not receive WDI. | By microarray analysis, at 24 hours 96 microRNAs were upregulated and 87 microRNAs downregulated in the injury severity 1 group (246 g, 2 cm). 66 microRNAs were upregulated and 63 microRNAs downregulated in the injury severity 2 group (246 g, 3 cm). 43 microRNAs were upregulated and 47 microRNAs downregulated in the injury severity 3 group (333 g, 2 cm). 46 microRNAs were upregulated and 48 microRNAs downregulated in the injury severity 4 group (333 g, 3 cm). At day 7, 30 microRNAs were upregulated and 6 microRNAs downregulated in the injury severity 1 group. 23 microRNAs were upregulated and 27 microRNAs downregulated in the injury severity 2 group. 11 microRNAs were upregulated and 4 microRNAs downregulated in the injury severity 3 group. 63 microRNAs were upregulated and 59 microRNAs downregulated in the injury severity 4 group. Three microRNAs (miR-296-5p, -154*, -466) were selected for validation by RT-PCR. Expression of all three was upregulated and similar to the expression pattern observed by microarray analysis. | No lesions were observed at and around the injury site in the brains of any of the injury groups. Altered microRNAs common to all the injury groups at both 24 hours and day 7 time points post-injury were analysed using Ingenuity Pathway Analysis for their correlation, with particular reference to acute and sub-acute pathologic processes. At 24 hours post-injury, a total of 81 pathways was predicted to be significantly affected by the combined effect of the significantly modulated microRNAs common to all the injury groups. Of the total of 81 pathways, 26 were relevant to neurological functions. Similar analysis of the significantly modulated microRNAs common to all the injury groups at 7 days post-injury indicated 73 pathways to be targeted by these microRNAs. Of the 73 pathways, 25 were relevant to neurological functions. | Varying intensities of mild TBI induced a differential microRNA expression profile in the brain post-injury. Pathways such as calcium and synaptic signaling were major targets of modulated microRNAs and may play a role in pathophysiology of mild TBI. |
| Sharma et al. (2014)             | C57B/6J mice, male, 11–12 weeks | Sham operated animals did not receive WDI. | By microarray analysis of serum at 3 hours, the number of significantly modulated microRNAs increased with increasing grade of injury except in the IS4 injury group where the numbers of significantly modulated microRNAs were marginally less than the IS3 injury group. 23 microRNAs (14 up- and 9 down-regulated) were significantly modulated in IS1 injury group. 53 microRNAs (35 up- and 18 down-regulated) were significantly modulated in IS2 injury group. 116 microRNAs (70 up- and 46 down-regulated) were significantly modulated in IS3 injury group. 106 microRNAs (66 up- and 40 down-regulated) were significantly modulated in IS4 injury group. 13 microRNAs (9 up- and 4 down-regulated) were found to be modulated in all four injury groups and had similar expression patterns. Expression of miR-214, -570a, -199a-3p was validated by RT-PCR. | Staining of brain section at hippocampus level (site of injury) did not show lesion volume in any of the injured groups indicating mild brain injury. Neurobehavioral severity scale-revised (NSS-R) scores increased with increase in fall height and weight of rod. Open field activity and acoustic startle response of the animals was reduced following injury. Several brain function related pathways such as axon guidance, gap junction, dopaminergic synapse, cholinergic synapse, long-term potentiation, tight junction, adherens junction, and long-term depression were targeted by the modulated microRNAs. 13 microRNAs were found to identify mild TBI regardless of its severity within the mild spectrum of injury. The more severe injuries were associated with a greater number of microRNAs involved in brain related functions. | |

*WI* was exposed and injury made over the left parietal lobe. WDI parameters were diameter of tip of rod 1 mm, weight of rod 246 and 333 g, fall height 2 and 3 cm for each of the two different weights of rod to produce increasing grade of mild TBI. Animals were sacrificed at 24 hours and day 7 post-injury (n = 3/group). Brain was exposed and full-depth brain tissue punch biopsies were done using a 4 mm tissue punch. The punch biopsy centered at the injury site of left parietal lobe was taken so that an area covering the injury as well as the surrounding site was included in the profiling analysis. The biopsy punch contained regions of the parietal lobe cortex, hippocampus, thalamus, mid brain, substantia nigra and amygdala. A separate group of animals for each of the injury and sham groups was used for histologic evaluation at 24 hours (n = 4/group) and day 7 (n = 4/group) post-injury.

Sham operated animals did not receive WDI.

Naive animals (n = 25). A separate group of sham animals (n = 6) was used for microRNA study.

Baseline measurements for behavioral studies were taken at day 3 before injury. Also measurements at 1, 14 and 30 days post-injury. A separate group of animals for all four injuries were used in the microRNA study (n = 6/group). Serum was collected at 3 hours post-injury, and whole brains were collected. Animal mortality immediately after the impact increased with increase in height of fall and weight of rod.

Sham operated animals did not receive WDI. By microarray analysis, at 24 hours 96 microRNAs were upregulated and 87 microRNAs downregulated in the injury severity 1 group (246 g, 2 cm). 66 microRNAs were upregulated and 63 microRNAs downregulated in the injury severity 2 group (246 g, 3 cm). 43 microRNAs were upregulated and 47 microRNAs downregulated in the injury severity 3 group (333 g, 2 cm). 46 microRNAs were upregulated and 48 microRNAs downregulated in the injury severity 4 group (333 g, 3 cm). At day 7, 30 microRNAs were upregulated and 6 microRNAs downregulated in the injury severity 1 group. 23 microRNAs were upregulated and 27 microRNAs downregulated in the injury severity 2 group. 11 microRNAs were upregulated and 4 microRNAs downregulated in the injury severity 3 group. 63 microRNAs were upregulated and 59 microRNAs downregulated in the injury severity 4 group. Three microRNAs (miR-296-5p, -154*, -466) were selected for validation by RT-PCR. Expression of all three was upregulated and similar to the expression pattern observed by microarray analysis.
Table 2 Continued

| Reference                  | No. of animals, gender, ages | Comparison | Changes in miRNAs in animals | Functional outcomes | Conclusion |
|----------------------------|------------------------------|------------|------------------------------|--------------------|------------|
| Sun et al. (2016)          | Sprague Dawley rats, male, 12 weeks. In the 3 days before TBI preparation, groups of animals received a single injection of 7 μL lentivirus encoding miR-23b (LV-miR-23b) or LV-miR NC into the right lateral ventricle. Skull was exposed and a steel disc 10 mm diameter, 3 mm thickness was adhered to the skull. WDL parameters were weight of rod 450 g, fall height 150 cm to produce moderate TBI. Neurological impairments were assessed using the modified neurological severity score (mNSS) test at 1, 3, 7 and 14 days post-injury. Also Morris Water Maze test carried out. Plasma collected and animals sacrificed at 1, 3, 7 and 14 days post-injury, and brains removed. | By RT-PCR, the levels of miR-23b were decreased in the plasma, hippocampus and cortex of TBI animals compared to sham group at 1, 3, 7 and 14 days post-injury. | Pretreatment of TBI animals with LV-miR-23b significantly reduced lesion volume of the contused hemisphere and brain edema compared with TBI group. Also mNSS score at 3, 7 and 14 days post-injury was decreased in group pretreated with LV-miR-23b. mNSS score in TBI group at 1 day post-injury was 9, indicative of moderate injury. On mNSS scale of severity: a score of 13–18 indicates severe injury, 7–12 indicates mean-moderate injury and 1–6 indicates mild injury (Zhang et al., 2013). LV-miR-23b pretreatment improved cognitive impairments in TBI animals. | MiR-23b may be a potential therapeutic target for TBI. |
| Ge et al. (2014)           | Sprague-Dawley rats, male, 12 weeks. A 3 mm craniotomy was made over the right parietal bone and Luer-lok end attached over the craniotomy. FPI parameters were pressure applied 1.8–2.0 atm, pulse duration not reported. Mortality rate was approx 5%. i.c.v. infusion was performed 10 minutes after FPI with miR-21 agomir, agomir negative control, miR-21 antagonist, antagonist negative control, and injury control at a rate of 1 μL/min. Animals sacrificed and brains removed. | By RT-PCR, miR-21 expression levels were detected in the impacted area with a 7 mm diameter including injured cerebral cortex and ipsilateral hippocampus at different time points from 0 hour to 14 days post-injury. The expression of miR-21 in the injury control group was increased at 6 hours post-injury, reached a peak at 3 days post-injury, and then gradually declined to baseline at 14 days post-injury. The miR-21 expression level was significantly increased (or decreased) in the agomir (or antagonist) group at 6 hours, 1 day and 3 days (or 6 hours and 1 day) post-injury compared to injury control group. | A significant decrease (or increase) in lesion volume was found in the agomir (or antagonist) group compared with the injury control group. The lesion volume was significantly correlated with mNSS score at day 14 post-injury. mNSS score for injury control group was 8 at day 1 post-injury indicating moderate TBI injury. Upr egulation of miR-21 in the brain improved the neurological outcome after FPI injury. MiR-21 regulated the expression of apoptotic and angiogenesis-related molecules in brain after TBI. The expression of Pten, a miR-21 target gene, was inhibited and Akt signaling was activated by miR-21 after TBI. | MiR-21 could be a potential therapeutic target for intervention after TBI. |
| Lei et al. (2009)          | Wistar rats, gender not reported, 8–9 weeks. A 3 mm craniotomy was made over the right parietal bone and plastic injury cap attached over the craniotomy site. FPI parameters were pressure applied 1.8–2.2 atm, pulse duration not reported, to produce moderate injury. Animals assigned to four groups corresponding to 6 hours, 24 hours, 48 hours, 72 hours post-injury (n = 2/group). Animals were sacrificed and brains removed. | By microarray analysis, of the 136 microRNAs detected at 6 hours post-injury, 13 were upregulated (> 2-fold) and 14 were downregulated (> 2-fold). In the detected 118 microRNAs expressed at 24 hours post-injury, 4 were upregulated (> 2-fold) and 23 were downregulated (> 2-fold). In the detected 149 microRNAs expressed at 48 hours post-injury, 16 were upregulated (> 2-fold) and 11 were downregulated (> 2-fold). In the detected 208 microRNAs expressed at 72 hours post-injury, 19 were upregulated (> 2-fold) and 5 were downregulated (> 2-fold). Upr egulation of miR-21 expression occurred at all four time points. MiR-21 was chosen as the candidate microRNA for validation by RT-PCR which confirmed the results of microarray analysis. | MiR-21 could be involved in the process of TBI course. | |
a GCS score of 9–12 for humans), most of the studies had used parameters to create a moderate TBI. In two of the ten studies (Sandhir et al., 2014; Meissner et al., 2016), the parameters chosen would more likely be associated with a mild-moderate brain injury. Many of the studies identified specific microRNAs as possible biomarkers and therapeutic targets. Meissner et al. (2016) reported the upregulated expression in cortex of miR-2137, -451, -218, -144, and the downregulated expression of miR-190, -137, -541, -107 at 1, 6 and 12 hours after TBI in mice compared to control. Similarly, miR-23a and miR-27a were downregulated in cortex of TBI mice as early as 1 hour and lasting up to 24 hours post-injury compared to control (Sabirzhanov et al., 2014). Liu et al. (2014) found that miR-142-3p, -144, -340-5p, -674-5p, -153, -186, -190, -132*, -138-1* were upregulated whereas let-7b was downregulated in hippocampus of TBI rats compared to controls. Additionally, miR-155 and miR-223 levels were significantly increased in mitochondrial fraction of hippocampus of TBI rats compared to controls (Wang et al., 2015). Interestingly, two studies examined microRNA profiles in mice given free access to a running wheel to exercise. The cortical levels of miR-21, -92a and -874 decreased while those of miR-138, -124 and let-7c increased compared with the TBI-non-runner group (Miao et al., 2015). Hu et al. (2015) observed the level of miR-21 was significantly elevated in hippocampus of TBI-non-runners compared with that of sham animals and the increase in miR-21 expression in hippocampus was reversed in TBI-runners. Also Sandhir et al. (2014) showed that basal expression of miR-21 was higher in the aged mice brain compared to adult brain. While miR-21 levels increased following TBI in adult mice with maximum increase at 24 hours post-injury, the age mice miR-21 expression in the brain was decreased after TBI.

**Strategies for TBI**

The alteration of microRNAs in different body fluids and tissues from the described human and animal studies is summarized in Table 3.

### MicroRNA Diagnostic and Therapeutic Strategies for TBI

The human studies have identified specific microRNAs in serum/plasma (miR-425-p, -21, -93, -191 and -499) and CSF (miR-328, -362-3p, -451, -486a) as possible indicators of the diagnosis, severity, and prognosis of TBI (Table 1). To date, there have been only a limited number of studies involving patients with TBI. These studies have included patients with mild, moderate, and severe TBI. However, such studies are important to increase the accuracy of diagnosis and outcomes, and refine treatments of injured patients. The early identification of biomarkers measured in samples collected within 1 hour from injury by the first responders (ambulance crew) at the injury scene before patients were admitted to hospital would allow clinicians to recognize and treat patients at risk of secondary brain injury and optimize early management. While the levels of specific microRNAs in serum or plasma may be developed into biomarkers for TBI, it is likely that other organs contribute to microRNAs in the blood (Sierzega et al., 2017) so that the circulating levels may not accurately reflect the levels of specific microRNAs in the brain itself. The microRNA profile in CSF would more reliably indicate alterations in the brain caused by TBI, since it is in direct contact with the extracellular matrix in the brain and its composition better reflects biochemical changes that occur in this organ. However, collection of CSF involves an invasive procedure and may not be easily accomplished in the elderly due to narrowing of the lumbar intervertebral space due to disc degeneration. Measurement of specific
Table 3: Summary of microRNA alterations in traumatic brain injury (TBI) of human patients and animal models

| Reference            | Species | Sample                        | Alteration of microRNA expression                                                                 |
|----------------------|---------|-------------------------------|----------------------------------------------------------------------------------------------------|
| Di Petro et al. (2017) | Human   | Serum                         | miR-21 and miR-335 at 4–12 hours, 48–72 hours and day 15 in severe TBI                            |
| You et al. (2016)    | Human   | Cerebro-spinal fluid (CSF)    | miR-141, -257, -181*, -27b*, -483-5p, -30b, -1289, -431*, -193b*, -499-3p of which miR-141 and miR-257 had the greatest change in severe TBI (coma) |
| Yang et al. (2016)   | Human   | Serum                         | miR-93, -191 and -499 in TBI over 24 hours to day 14 with the levels highest in severe TBI         |
| Sun et al. (2016)    | Human   | Plasma                        | miR-23b was decreased in TBI with the levels lowest in severe TBI                                  |
| Bhomia et al. (2016) | Human   | Serum, CSF                    | miR-151-5p, -195, -20a, -328, -362-3p, -30d, -451, -486, -505*, -92a in serum; miR-328, -362-3p, -451, -486 in CSF |
| Redell et al. (2010) | Human   | Plasma                        | miR-16 and miR-92a at 0–10 hours in mild TBI; miR-765 at 68 hours in severe TBI                    |
| Sabirzhanov et al. (2016) | Mouse | Cerebral cortex               | miR-711 in moderate TBI as early as 1 hour post-injury, peaking at 6 hours, and persisting through to 72 hours. |
| Meissner et al. (2016) | Mouse | Cerebral cortex               | miR-2137, -451, -21*, -144, -184 in mild-moderate TBI                                            |
| Miao et al. (2015)   | Mouse   | Cerebral cortex               | miR-21, -92a and -874 in moderate TBI-non-runners                                                  |
| Hu et al. (2015)     | Mouse   | Hippocampus                   | miR-21 in moderate TBI-non-runners                                                                  |
| Sandhir et al. (2014) | Mouse | Cerebral cortex               | miR-21 in mild-moderate TBI with maximum increase at 24 hours post-injury (adult)                  |
| Sabirzhanov et al. (2014) | Mouse | Cerebral cortex               | miR-23a-3p and miR-27a-3p in moderate TBI (aged)                                                  |
| Wang et al. (2015)   | Rat     | Hippocampus                   | mitochondrial-associated miR-155 and miR-223 in moderate TBI at 12 hours post-injury; miR-155, -223, -146a, -142-3p, -142-5p, -150 expression highest in enriched microglia and astrocytes, miR-124a expression highest in cortical neurons |
| Sun et al. (2014)    | Rat     | Hippocampus                   | miR-142-3p in moderate TBI at day 5 post-injury; miR-221 in moderate TBI at 1, 3 and 5 days post-injury |
| Liu et al. (2014)    | Rat     | Hippocampus                   | miR-142-3p, -144, -340-5p, -674-5p, -153, -186, -190, -132*, -138-1* in moderate TBI at 1 hour, 1, 3, 5 and 7 days post-injury |
| Hu et al. (2012)     | Rat     | Dorsal hippocampus            | miR-153 in moderate TBI at 24 hours post-injury                                                   |
| Chandran et al. (2017) | Mouse | Brain tissue biopsy           | miR-296-5p, -154*, -466 in mild TBI in mild TBI at 24 hours and 7 days post-injury                  |
| Sharma et al. (2014) | Mouse   | Serum                         | number of microRNAs increased with increasing grade of injury except for IS4 injury group in mild TBI at 3 hours post-injury |
| Sun et al. (2016)    | Rat     | Plasma, cerebral cortex, hippocampus | Number of microRNAs increased with increasing grade of injury except for IS4 injury group in mild TBI at 3 hours post-injury |
| Ge et al. (2014)     | Rat     | Cerebral cortex/hippocampus   | miR-21 in moderate TBI at 6 hours and 3 days post-injury                                           |
| Lei et al. (2009)    | Rat     | Brain tissue                  | miR-21 in moderate TBI at 6 hours, 1, 2 and 3 days post-injury                                     |

Plasma microRNAs have the potential to improve TBI patient classification and possibly clinical management.
microRNAs in the serum/plasma or CSF of human patients enables mild TBI to be recognized and distinguished from severe TBI. At present, many cases of mild TBI go unnoticed or misdiagnosed, as the current diagnostic tests are neither sensitive nor specific enough to identify individuals who have sustained a mild TBI (Belanger et al., 2007; Dash et al., 2010).

The animal studies have examined specific microRNAs as biomarkers and therapeutic targets for moderate and mild TBI (e.g., miR-21, miR-23b) (Table 2). No studies were found on microRNA expression levels in animals subjected to severe TBI, presumably because of the likely high mortality rate and ethical concerns. Several of the studies had examined the effect of voluntary exercise on microRNA profiling and shown to be altered by exercise. In addition, differences in basal microRNA expression in the brain of adult and aged animals and alterations in response to TBI (e.g., miR-21) have been reported. The latter is very relevant as persons aged ≥ 75 have an increasing incidence of fall-related TBI.

Downstream targets of several important microRNAs have been indicated in the studies reviewed. For example, miR-23b specifically targeted to 3'-UTR of autophagy-related protein 12 (ATG12) mRNA in human TBI patients (Sun et al., 2016). Also upregulation of miR-711 inhibited Akt expression in the injured mouse cortex as early as 1 hour post-injury. TBI resulted in increased levels of pro-apoptotic proteins PUMA and two isoforms of Bim large and small, which are regulators of apoptosis upstream of mitochondrial release of allograft inflammatory factor 1 (AIF-1) and cytochrome c (Sabirzhano et al., 2016). MiR-21 regulated cell survival, invasiveness and apoptosis through specific mRNA targets that included PTEN, which was upregulated by 3.8-fold in the mouse adult brain 24 hours post-injury (Sandhir et al., 2014). Post-injury decreases in miR-23a and miR-27a contributed to neuronal cell death in mouse brain after TBI by upregulating proapoptotic Bcl-2 family members (Sabirzhano et al., 2014). In rat hippocampus, upregulated miR-221 may regulate cell proliferation and angiogenesis by PDGF signaling pathway at the early stages after TBI (Sun et al., 2014). A decrease was detected in expression of NRFR2, the protein of Nfe2l2 gene that is a putative target of both the upregulated microRNAs, miR-144 and miR-153, in rat hippocampus post-TBI injury. SNCA, one of the target proteins of miR-153, was also significantly suppressed in the hippocampus after TBI (Liu et al. 2014). In injured rat cerebral cortex and hippocampus, upregulated miR-21 modulated the expression of apoptotic and angiogenesis-related molecules in brain after TBI. The expression of Pten, a miR-21 target gene, was inhibited and Akt signaling was activated by miR-21 after TBI (Ge et al., 2014). The mature mRNAs predicted to be targeted by the upregulated microRNAs in human patients with TBI are involved in major TBI related pathways such as erythropoietin signaling, G protein coupled receptor signaling, GABA receptor signaling and neuropathic pain signaling in dorsal horn neurons (Bhomia et al., 2016). Several brain function related pathways such as axon guidance, gap junction, dopaminergic synapse, cholinergic synapse, long-term potentiation, tight junction, adherens junction, and long-term depression were targeted by the modulated microRNAs in injured mouse brain (Sharma et al., 2014).

Wang et al. (2015) examined miR-155, -223, -146a, -142-3p, -142-5p, -150, -124a expression in enriched cortical neuron, astrocyte and microglial cultures of injured rats. MiR-155, -223, -146a, -142-3p, -142-5p, -150 were detected in all three cell types but showed the highest expression in microglia and astrocytes, whereas levels of miR-124a were highest in cortical neurons. While not included in this review, other studies have examined the actions of specific microRNAs in cultures of cortical neurons (Han et al., 2014; Ma et al., 2016).

**Future Perspectives**

At the present time, there is no effective treatment for TBI due, in part, to the widespread impact of numerous complex secondary biochemical and pathophysiological events occurring at different time points following the initial injury (Rosenfeld et al., 2012). These secondary injury events include edema, glutamate excitotoxicity, inflammation, oxidative stress damage, activation of apoptosis, necrosis and autophagy, and impaired mitochondrial function (Raghupathi, 2004; Singh et al., 2006; Ziebell and Morganti-Kossmann, 2010). The earliest and most severe neuropathological changes occur in the hippocampus after TBI (Orrison et al., 2009; Fanselow and Dong, 2010). The hippocampus, a key brain structure for learning and memory, is particularly vulnerable to TBI. The molecular mechanisms underlying hippocampal alterations and cognitive impairments following TBI are unclear and further studies are warranted.

A single microRNA can regulate the expression of hundreds of target genes, so alterations in a panel of microRNAs could greatly affect the pathophysiology and outcome of TBI. Identification of specific genes and signal transduction pathways directly involved in TBI is essential for development of novel therapeutic strategies.

Evidences have also shown that several aspects of the response to brain injury are altered in aged animals. These include worsening of behavioral outcomes, increase of inflammatory responses to injury, and decrease of neuroprotective responses (Sandhir et al., 2004, 2008; Anderson et al., 2009; Sandhir and Berman, 2010). In the aged brain following injury there is increased blood-brain barrier (BBB) permeability accompanied by increased matrix metalloproteinase-9 activity and decreased BBB repair processes (Lee et al., 2012). These changes are all likely to result from altered gene and protein expressions after injury. Voluntary exercise by individuals with TBI (e.g., treadmill, exercycle) could aid recovery of TBI patients.

Plasma microRNAs have the potential to improve TBI patient classification and possibly clinical management. Combining plasma levels of miR-16, -92a and -765, 100% sensitivity and 100% accuracy could be achieved in identifying severe TBI patients (Redell et al., 2010). It is possible that a panel of specific circulating microRNAs could achieve 100% sensitivity and 100% accuracy in identifying mild TBI.
Bhomia et al. (2016) identified a panel of 10 unique microRNAs for the diagnosis of mild/moderate TBI and severe TBI. Temporal expression of specific microRNAs may be used as a molecular marker for assessment of TBI progression and inference of damage time. At the present time there are concerns about the specificity of human biofluid biomarkers such as S100β, glial fibrillary acid protein, neuron-specific enolase, and tau protein for TBI. Many investigators have failed to detect associations between serum levels of S100β and CT abnormalities. The utility of S100β in the setting of multiple trauma remains controversial because it is also elevated in trauma patients without head injuries (Papa et al., 2015). A study by Papa et al. (2012) indicated that serum glial fibrillary acid protein had good specificity for brain injury acutely after injury, although it is also detected in patients with non-TBI injuries. Studies with the serum biomarker neuron-specific enolase concluded that it had limited utility as a marker of neuronal damage (Fridriksson et al., 2000). A proteolytically cleaved form of tau protein, c-tau, was significantly elevated in CSF in TBI patients and the levels correlated with clinical outcome (Shaw et al., 2002). Although levels of c-tau were also elevated in plasma from patients with severe TBI, there was no correlation between plasma levels and clinical outcome (Chattfield et al., 2002). There clearly is a need for identifying and innovating sensitive and reliable new TBI biomarkers.

A strong association has been shown between TBI and later development of ischemic stroke that remained significant even after several potential confounders, such as vascular risk factors and comorbidities, were taken into consideration. Specific biomarkers for ischemic stroke have been reported (Martinez and Peplow, 2016). Further large-scale studies with TBI patients are needed to provide more information on the changes in microRNA profiles in different age groups (children, adults, and elderly). Future studies should assess the values of the altered microRNAs in TBI to other measures of injury severity according to assessments other than the GCS such as duration of coma and the duration of post-traumatic amnesia. Also as hypertension is a common comorbidity in such as duration of coma and the duration of post-traumatic amnesia. Also as hypertension is a common comorbidity in

References

Adekoya N, Thurman DJ, White DD, Webb KW (2002) Surveillance for traumatic brain injury deaths--United States, 1989-1998. MMWR Surveill Summ 51:1-14.

Alder J, Fujioka W, Lifshitz J, Crockett DP, Thakker-Varia S (2011) Lateral fluid percussion: model of traumatic brain injury in mice. J Vis Exp (54):3063.

Ambros V (2004) The functions of animal microRNAs. Nature 431:350-355.

Anderson J, Sandhir R, Hamilton ES, Berman NE (2009) Impaired expression of neuroprotective molecules in the HIF-1 pathway following traumatic brain injury in aged mice. J Neurotrauma 26:1557-1566.

Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP (2008) The impact of microRNAs on protein output. Nature 455:64-71.

Belanger H, Vanderploeg R, Cartiss G, Warden DL (2007) Recent neuroimaging techniques in mild traumatic brain injury. J Neuropsychiatry Clin Neurosci 19:5-20.

Bhomia M, Balakarthisesan NS, Wang KK, Papas L, Maheshwari BR (2016) A panel of serum miRNA biomarkers for the diagnosis of severe to mild traumatic brain injury in humans. Sci Rep 6:28148.

Bügin S, Guclu-Gunduz A, Oruckaplan H, Kose N, Celik B (2012) Gait and Glasgow Coma Scale scores can predict functional recovery in patients with traumatic brain injury. Neurologen Res 7:1978-1984.

Chandran R, Sharma A, Bhomia M, Balakarthisesan NS, Knollmann-Bögel S, Maheshwari R (2017) Differential expression of microRNAs in the brains of mice subjected to increasing grade of mild traumatic brain injury. Brain Inj 31:106-119.

Chattfield DA, Zemlan FP, Day DJ, Menon DK (2002) Discordant temporal patterns of S100β and cleaved tau protein elevation after head injury: a pilot study. Br J Neurosurg 16:471-476.

Dash PK, Zhao J, Hergenroeder G, Moore AN (2010) Biomarkers for the diagnosis, prognosis, and evaluation of treatment efficacy for traumatic brain injury. Neurotherapeutics 7:100-114.

Davis LM, Pauly JR, Readnower RD, Rho JM, Sullivan PG (2008) Fast imaging is neuroprotective following traumatic brain injury. J Neurosci Res 86:1812-1822.

Di Pietro V, Ragusa M, Davies D, Su Z, Hazelndine J, Lazzarino G, Hill J, Crombie N, Foster M, Purrello M, Logan A, Belli A (2017) MicroRNAs as novel biomarkers for the diagnosis and prognosis of mild and severe traumatic brain injury. J Neurotrauma 34:1948-1956.

Fanselow MS, Dong HW (2010) Are the dorsal and ventral hippocamrais functionally distinct structures? Neuron 65:7-19.

Fischer H (2013) U.S. Military Casualty Statistics: Operation New Dawn, Operation Iraqi Freedom, and Operation Enduring Freedom. CRS Report for Congress. Prepared for Members of Congress: Congressional Research Service:1-12.

Fridriksson T, Kini N, Walsh-Kelly C, Hennes H (2000) Serum neuron-specific enolase as a predictor of intracranial lesions in children following head trauma: A pilot study. Acad Emerg Med 7:816-820.

Ge XT, Lei P, Wang HC, Zhang AL, Han ZL, Chen X, Li SH, Jiang RC, Kang CS, Zhang JN (2014) miR-21 improves the neurological outcome after traumatic brain injury in rats. Sci Rep 4:6718.

Gennarelli TA (2014) Future directions in brain injury research. Prog Neurosurg 28:243-250.

Gilmer LR, Roberts KN, Joy K, Sullivan PG, Scheff SW (2009) Early mitochondrial dysfunction after cortical contusion injury. J Neurotrauma 26:1271-1280.

Han Z, Chen F, Ge X, Tan J, Lei P, Zhang J (2014) miR-21 alleviated apoptosis of cortical neurons through promoting PTEN-Akt signaling pathway in vitro after experimental traumatic brain injury. Brain Res 1582:12-20.

Holcomb EM, Millis SR, Hanks RA (2012) Comorbid diseases in persons with traumatic brain injury: descriptive findings using the modified cumulative illness rating scale. Arch Phys Med Rehabil 93:1338-1342.

Hu T, Zhou FJ, Chang YF, Li YS, Liu GC, Hong Y, Chen HL, Xiyang YB, Bao TH (2015) miR21 is associated with the cognitive improvement following voluntary running wheel exercise in TBI mice. J Mol Neurosci 57:114-122.

Hu Z, Yu D, Almeida-Suhett C, Tu K, Marini AM, Eiden L, Braga MF, Zhu J, Li Z (2012) Expression of miRNAs and their cooperative regulation of the pathophysiology in traumatic brain injury. PLoS One 7:e39357.

Jennett B (1988) Epidemiology of head injury. Arch Dis Child 78:403-406.
Kabadi SV, Hilton GD, Stoica BA, Zapple DN, Faden AI (2010) Fluid- 
perfusion-induced traumatic brain injury model in rats. Nat Protoc 5:1552-1563.

Kesler SR, Adams HF, Bigler ED (2000) SPECT, MR and quantitative MR imaging: correlates with neuropsychological and psychological outcome in traumatic brain injury. Brain Inj 14:851-857.

Lee P, Kim J, Williams R, Sandhir R, Gregory E, Brooks WM, Berman NE (2012) Effects of aging on blood brain barrier and matrix metalloproteinases following controlled cortical impact in mice. Exp Neurol 234:50-61.

Lei P, Li Y, Chen X, Yang S, Zhang J (2009) Microarray based analysis of microRNA expression in rat cerebral cortex after traumatic brain injury. Brain Res 1284:191-201.

Leo P, McCrea M (2016) Epidemiology. In: Translational Research in Traumatic Brain Injury (Laskowitz D, Grant G, eds). Boca Raton: CRC Press/Taylor and Francis Group.

Lighthall JW (1988) Controlled cortical impact: a new experimental brain injury model. J Neurotrauma 5:1-15.

Liu L, Sun T, Liu Z, Chen X, Zhao L, Qiu G, Li Q (2014) Traumatic brain injury dysregulates microRNAs to modulate cell signaling in rat hippocampus. PLoS One 9:e103948.

Ma J, Shui S, Han X, Guo D, Li T, Yan L (2016) microRNA-22 attenuates neuronal cell apoptosis in a cell model of traumatic brain injury. Am J Transl Res 8:1895-1902.

Maas AI, Steyerberg EW, Murray GD, Bullock R, Baethmann A, McCrea M (2016) Epidemiology. In: Translational Research in Traumatic Brain Injury (Laskowitz D, Grant G, eds). Boca Raton: CRC Press/Taylor and Francis Group.

Martinez B, Peplow PV (2016) Blood microRNAs as potential diagnostic markers in cerebral ischemic injury, Neural Regen Res 11:1375-1378.

Meissner L, Gallozzi M, Balbi M, Schwarzmaier S, Tiedt S, Terpolilli M (1994) A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 80:2910-2300.

Martinez B, Peplov PV (2016) Blood microRNAs as potential diagnostic tools for brain injury. J Neurotrauma 33:713-720.

Miao W, Bao TH, Han JH, Yin M, Yan Y, Wang WW, Zhu YH (2015) Voluntary exercise prior to traumatic brain injury alters miRNA expression in contused mouse cerebral cortex. Braz J Med Biol Res 48:433-439.

Orrison WW, Hanson EH, Alamo T, Watson D, Sharma M, Perkins TG, Tandy RD (2009) Traumatic brain injury: a review and highlights of GMR findings in 100 unarmad combatants using a literature-based checklist. J Neurotrauma 26:689-701.

Papa L, Lewis LM, Falk JL, Zhang Z, Silvestri S, Giordano P, Demery AI, Stocchi N, Bullock R (2008) Moderate and severe traumatic brain injury in adults. Lancet Neurol 7:728-741.

Marmarou A, Foda MA, van den Brink W, Campbell J, Kita H, Demetriou K (1994) A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 80:2910-2300.

Meissner L, Gallozzi M, Balbi M, Schwarzmaier S, Tiedt S, Terpolilli M (1994) A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 80:2910-2300.

Martinez B, Peplov PV (2016) Blood microRNAs as potential diagnostic markers in cerebral ischemic injury, Neural Regen Res 11:1375-1378.

Meissner L, Gallozzi M, Balbi M, Schwarzmaier S, Tiedt S, Terpolilli M (1994) A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 80:2910-2300.

Martinez B, Peplov PV (2016) Blood microRNAs as potential diagnostic markers in cerebral ischemic injury, Neural Regen Res 11:1375-1378.

Meissner L, Gallozzi M, Balbi M, Schwarzmaier S, Tiedt S, Terpolilli M (1994) A new model of diffuse brain injury in rats. Part I: Pathophysiology and biomechanics. J Neurosurg 80:2910-2300.

Martinez B, Peplov PV (2016) Blood microRNAs as potential diagnostic markers in cerebral ischemic injury, Neural Regen Res 11:1375-1378.